Due to covid, non-urgent operations were all ceased in many states - even with that non-covid testing increased by 2% which in itself is impressive.
They had non-covid rev of 258.2m$ last half. Medlab had no contribution in this.
EBIT margin came at 35.5% - a lot has to do with covid testing. Before medlab acquisition that was around 21%.
Medlab acquisition will give them scale, margin for non-covid revenue should be around 23-25%. Lets assume 23%.
Medlab had FY21 rev of 93m$. They are expecting 20m$ of EBIT from medlab acquisition for whole year from FY23.
Assuming 2.8% growth again for non-covid rev gives: 265m$ for the half
@ EBIT margin of 23% [taking the lower value]: 60.95m$ for the half.
They used to pay around 12m$ as interest payments - since now they have paid off their loan - inluding 4m$ a year anyways to count for small loans etc; that still gives 8m$ of savings which will go into EBIT increase.
extrapolating to the whole year, EBIT: 149.9 ~ 150m$ EBIT from non covid testing for the whole year. 30% tax: 45m$
NPAT: 105m$
This is with ZERO covid rev:
PE @ 4.73: 9.
Still ridiculously cheap for pretty much all medicare covered payments.
Add in all the revenue from covid testing
- WA today had more than 1000 cases - its like a virgin territory for covid. there will be plenty of rev to me made.
- still plenty of cases in eastern states.
- Covid testing will stay FOREEVER! - scale will change.
- international borders will open and taht will bring more cases.
- any new variant and it will go gangbusters.
- NON-covid revenue above is very conservative. It will definitely be more since now there will be no restrictions.
- generally australian population is getting older - more pathology testing.
PS: how is ur rocket on APX going?
- Forums
- ASX - By Stock
- ACL
- Ann: Media Release - 1H22 Financial Results
Ann: Media Release - 1H22 Financial Results, page-6
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
Add ACL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$3.63 |
Change
-0.110(2.94%) |
Mkt cap ! $732.6M |
Open | High | Low | Value | Volume |
$3.71 | $3.76 | $3.62 | $2.650M | 723.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 7666 | $3.62 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.65 | 7000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 10289 | 3.600 |
1 | 142 | 3.590 |
1 | 3000 | 3.570 |
1 | 7000 | 3.520 |
2 | 2500 | 3.500 |
Price($) | Vol. | No. |
---|---|---|
3.730 | 7762 | 1 |
3.740 | 1350 | 1 |
3.750 | 14483 | 3 |
3.770 | 3000 | 1 |
3.800 | 4775 | 4 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
ACL (ASX) Chart |